Indian healthcare M&A, without the noise.

India's hospital sector has entered its most active M&A cycle since 2015. Listed chains — Apollo, Manipal, Max, Aster, Fortis and Narayana — are competing with global PE for a shrinking pool of quality mid-market assets. The battleground is no longer Tier-1 metros; it is Tier-2 cities with 100–300 bed flagships and clean promoter cap tables.

For a well-run 150-bed Tier-2 multi-specialty hospital with 18–22% EBITDA margin, we're seeing EV/EBITDA multiples land in the 14–18x range, with strategic buyers paying the top of the band for assets that plug a geographic gap. Diagnostic chains with 25+ centres and IVF platforms with proven clinical outcomes are transacting at 4–6x revenue and 18–24x EBITDA respectively.

Promoters exploring an exit or partnership in 2026 should expect diligence intensity to have stepped up materially — audited MIS for three years, clinical KPIs by department, doctor retention terms, and NABH renewal timelines are now table stakes rather than nice-to-haves.

Healthcare is one of the few sectors where announcing you're exploring a sale can materially damage the asset. Doctors update their LinkedIns, TPAs renegotiate, patients defer elective procedures, and competitors pounce on senior clinical talent. A promoter can lose a year of enterprise value in ninety days.

Anonymous listings solve this at the platform layer, not through discretion alone. On ClinicalMerger, buyers see banded metrics — region, city tier, bed count band, revenue band, EBITDA band, ask band — with your brand, exact location, licences and photographs hidden until you personally approve an NDA request that our desk has already vetted.

The mechanic works because banded data is enough for a serious institutional buyer to decide whether an opportunity fits their mandate, but not enough for anyone in the market to identify the asset. It is the same principle bulge-bracket banks use in their teaser packs — productised into a live, always-on marketplace.

Institutional legitimacy is the whole product for a seller. Before any buyer is granted browse access, our desk validates: entity registration and beneficial ownership, active mandate in Indian healthcare M&A, deployable capital appropriate to the deal band, prior transaction record where applicable, and no pending regulatory action against the entity or its principals.

For corporate hospital networks we validate the acquisition committee and the sponsoring board member. For PE funds we validate the current fund vintage, dry powder and stated healthcare allocation. For family offices we validate discretionary authority and prior healthcare exposure.

The result: when a promoter sees an NDA request, they are looking at a counterparty that has been triaged by our desk. Sellers still have full control — they approve or decline every NDA — but the noise floor has been removed.